Search Results - "Reinisch, W."

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target by Peyrin-Biroulet, L, Sandborn, W, Sands, B E, Reinisch, W, Bemelman, W, Bryant, R V, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, P L, Loftus, Jr, E V, Marteau, P, Munkholm, P, Murdoch, T B, Ordás, I, Panaccione, R, Riddell, R H, Ruel, J, Rubin, D T, Samaan, M, Siegel, C A, Silverberg, M S, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, J-F

“…The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory…”
Get full text

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease by Rahier, J.F., Magro, F., Abreu, C., Armuzzi, A., Ben-Horin, S., Chowers, Y., Cottone, M., de Ridder, L., Doherty, G., Ehehalt, R., Esteve, M., Katsanos, K., Lees, C.W., MacMahon, E., Moreels, T., Reinisch, W., Tilg, H., Tremblay, L., Veereman-Wauters, G., Viget, N., Yazdanpanah, Y., Eliakim, R., Colombel, J.F.

Get full text

International Reference Ionosphere 2007: Improvements and new parameters by Bilitza, D., Reinisch, B.W.

“…The International Reference Ionosphere (IRI), a joint project of URSI and COSPAR, is the de facto international standard for the climatological specification…”
Get full text

Global Ionospheric Radio Observatory (GIRO) by Reinisch, Bodo W., Galkin, Ivan A.

“…Digisonde ionospheric sounders installed at 80+ locations in the world have gradually evolved their generally independent existence into a Global Ionospheric…”
Get full text

Field-aligned distribution of the plasmaspheric electron density: An empirical model derived from the IMAGE RPI measurements by Ozhogin, P., Tu, J., Song, P., Reinisch, B. W.

“…We present a newly developed empirical model of the plasma density in the plasmasphere. It is based on more than 700 density profiles along field lines derived…”
Get full text

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease by Rosario, M., Dirks, N. L., Gastonguay, M. R., Fasanmade, A. A., Wyant, T., Parikh, A., Sandborn, W. J., Feagan, B. G., Reinisch, W., Fox, I.

“…Summary Background Vedolizumab, an anti‐α4β7 integrin monoclonal antibody (mAb), is indicated for treating patients with moderately to severely active…”
Get full text

Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti‐TNF‐α therapy by Danese, S., Fiorino, G., Reinisch, W.

“…Aliment Pharmacol Ther 2011; 34: 1–10 Summary Background  The addition of antitumour necrosis factor‐α (TNF‐α) agents to the therapeutic armamentarium against…”
Get full text

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I by Reinisch, W., Wang, Y., Oddens, B. J., Link, R.

“…Summary Background Secondary loss of response to anti‐TNF‐α therapy is observed in Crohn's disease patients. Aim Serum C‐reactive protein (CRP) levels at…”
Get full text

Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies by Reinisch, W., Lindgren, S.

“…Linked ContentThis article is linked to Aksan et al papers. To view these articles visit https://doi.org/10.1111/apt.14269 and…”
Get full text

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis by Colombel, J.‐F., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rutgeerts, P., Tang, K. L., Oortwijn, A., Bevelander, G. S., Cornillie, F. J., Sandborn, W. J.

“…Summary Background As treatment goals in Crohn's disease (CD) evolve, targets now include clinical remission (CR), mucosal healing (MH) and biological…”
Get full text

Review article: defining remission in ulcerative colitis by Travis, S. P. L., Higgins, P. D. R., Orchard, T., Van Der Woude, C. J., Panaccione, R., Bitton, A., O’Morain, C., Panés, J., Sturm, A., Reinisch, W., Kamm, M. A., D’Haens, G.

“…Aliment Pharmacol Ther 2011; 34: 113–124 Summary Background  There is no international agreement on scoring systems used to measure disease activity in…”
Get full text

Whistler-Mode Radiation From a Dipole Antenna in Cold Magnetized Plasma by Song, Paul, Tu, Jiannan, Reinisch, Bodo W., Galkin, Ivan A., Johnston, William R.

“…We treat whistler-mode radiation from a dipole antenna in a cold magnetized plasma based on the Fresnel zone construction theory. Radiated waves from the…”
Get full text

Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience by Danese, S., Colombel, J.‐F., Reinisch, W., Rutgeerts, P. J.

“…Aliment Pharmacol Ther 2011; 33: 857–869 Summary Background  Crohn’s disease is a progressive condition, with most patients developing a penetrating or…”
Get full text

Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future by Danese, S., Colombel, J.‐F., Peyrin‐Biroulet, L., Rutgeerts, P., Reinisch, W.

“…Summary Background Until recently, the management of ulcerative colitis (UC) consisted of the stepwise use of mesalazine, corticosteroids and immunomodulators,…”
Get full text

The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐TNF‐α naïve Crohn's disease by Narula, N., Kainz, S., Petritsch, W., Haas, T., Feichtenschlager, T., Novacek, G., Eser, A., Vogelsang, H., Reinisch, W., Papay, P.

“…Summary Background TNFα antagonists, including infliximab (IFX) and adalimumab (ADA), have revolutionised treatment for Crohn's disease. Studies comparing…”
Get full text

Systematic review: instruments to assess abdominal pain in irritable bowel syndrome by Mujagic, Z., Keszthelyi, D., Aziz, Q., Reinisch, W., Quetglas, E. G., De Leonardis, F., Segerdahl, M., Masclee, A. A. M.

“…Summary Background Consensus on standard methods to assess chronic abdominal pain in patients with irritable bowel syndrome (IBS) is currently lacking. Aim To…”
Get full text

Whistler‐Mode Transmission Experiments in the Radiation Belts: DSX TNT Circuit Simulation and Data Analysis by Tu, Jiannan, Song, Paul, Galkin, Ivan A., Reinisch, Bodo W., Johnston, William R., Starks, Michael J., Su, Yi‐Jiun, Cooke, David, Ginet, Gregory P., Inan, Umran S., Lauben, David S., Miyoshi, Yoshizumi, Matsuda, Shoya, Kasahara, Yoshiya, Kojima, Hirotsugu, Shinohara, Iku

“…High‐power transmission experiments in the very low frequency (VLF) mode have been conducted by the US Air Force Research Laboratory’s Demonstration and…”
Get full text

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE by Löfberg, Robert, Louis, Edouard V., Reinisch, Walter, Robinson, Anne M., Kron, Martina, Camez, Anne, Pollack, Paul F.

“…Background: Data regarding the effectiveness of anti‐tumor necrosis factor (TNF) agents for resolution of extraintestinal manifestations (EIMs) are scarce. The…”
Get full text

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location? Authors’ reply by Narula, N., Reinisch, W.

Get full text

Anaemia in inflammatory bowel disease: a population‐based 10‐year follow‐up by Høivik, M. L., Reinisch, W., Cvancarova, M., Moum, B.

“…Summary Background The point prevalence estimates of anaemia in patients with inflammatory bowel disease (IBD) range between 6% and 74%. The variation is…”
Get full text